Aurobindo Pharma gets USFDA nod for Amlodipine, Benazepril Capsules

07 Sep 2012 Evaluate

Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Amlodipine Besylate and Benazepril Hydrochloride Capsules 2.5mg/10mg, 5mg/20mg, 5mg/40mg, 10mg/20mg, and 10mg/40mg (ANDA 202239). The products are ready for launch.

Amlodipine Besylate and Benazepril Hydrochloride Capsules are the generic bioequivalent to the reference listed drug Lotrel Capsules of Norvatis Pharmaceutical Corp. According to IMS, the annual sales of Amlodipine Besylate and Benazepril Hydrochloride Capsules is about $500 million for the twelve months ending March 2012.

The products have been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India. The company now has a total of 158 ANDA approvals - 133 final approvals including 1 from Aurolife Pharma LLC and 25 tentative approvals from USFDA.

Aurobindo Pharma has a product presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc. The company is the market leader in semi-synthetic penicillin drugs.

Aurobindo Pharma Share Price

1171.40 9.55 (0.82%)
10-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.25
Dr. Reddys Lab 1251.10
Cipla 1489.15
Zydus Lifesciences 923.70
Lupin 2055.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×